Claret Bioscience

Executive Summary

Claret Bioscience, founded in 2018 and headquartered in San Francisco, is a biotechnology company specializing in advanced molecular analysis tools for next-generation sequencing. The company focuses on library preparation kits designed to handle degraded DNA and RNA, particularly cell-free DNA (cfDNA), FFPE samples, and ancient DNA. Claret's core innovation lies in preserving native molecular ends, enabling a complete and unaltered view of nucleic acid fragments. This approach addresses a critical bottleneck in genomics research and liquid biopsy applications, where sample quality often limits data accuracy. By providing robust solutions for challenging sample types, Claret aims to enhance the reliability of NGS workflows in both research and biopharmaceutical settings. The market for NGS library preparation is expanding rapidly, driven by the growing adoption of liquid biopsies for cancer screening, prenatal testing, and infectious disease monitoring. Claret's focus on degraded DNA positions it well to capture share in adjacent segments like forensic genomics and ancient DNA analysis. While the company operates in a competitive landscape dominated by larger players (e.g., Illumina, New England Biolabs), its proprietary end-preservation chemistry offers a differentiated value proposition. Given the increasing demand for high-fidelity genomics data and the scarcity of specialized solutions for low-quality samples, Claret is poised for growth. However, as a private, pre-revenue-stage company with no disclosed funding, execution risk remains high.

Upcoming Catalysts (preview)

• TBDLaunch of enhanced cfDNA library prep kit for liquid biopsy70% success
• TBDStrategic partnership with diagnostic company for clinical validation50% success
• TBDSeries A funding round to scale commercial operations60% success